Windtree Therapeutics Inc (WINT) SEC Filing 8-K Material Event for the period ending Thursday, October 25, 2018

Windtree Therapeutics Inc

CIK: 946486 Ticker: WINT

View differences made from one to another to evaluate Windtree Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Windtree Therapeutics Inc.


Assess how Windtree Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Windtree Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Windtree Therapeutics Inc provided additional information to their SEC Filing as exhibits

Ticker: WINT
CIK: 946486
Form Type: 8-K Corporate News
Accession Number: 0001437749-18-018817
Submitted to the SEC: Thu Oct 25 2018 4:27:44 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: